Browse the evidence

Genetic variants (SNPs) associated with obesity, diabetes, and cardiovascular disease generally have small effect sizes and explain a small fraction of the overall variance in these conditions.

Understanding your genetics does not give you a free pass or a guaranteed outcome. Most genetic risks are small and can be managed. Focus on modifiable risk factors like BMI, blood pressure, and diet quality.

Implementation of Enhanced Recovery After Surgery (ERAS) protocols in bariatric surgery significantly reduces postoperative nausea and vomiting, intraoperative time, time to mobilization, intensive care unit stay, and total/functional hospital stay compared to standard care, without increasing complication rates.

For bariatric surgery units, adopting ERAS protocols is a high-value intervention. It significantly reduces patient suffering (nausea/vomiting), shortens hospital stays, and speeds up mobilization without increasing surgical risks like leaks or bleeding. Implementation should be prioritized where feasible.

Race and geographic region significantly modify the risk of new-onset diabetes in people with HIV, with higher rates observed in South Asia and among Black or African American individuals in high-income regions.

If you are from South Asia or are Black/African American, you may have a higher baseline risk for diabetes. Work with your healthcare provider to monitor your blood sugar and weight closely, as these risks can be managed with lifestyle changes.

Existing FDA-approved smoking cessation medications (varenicline, nicotine replacement therapy, and bupropion alone) provide only modest attenuation of post-cessation weight gain and do not eliminate it.

Standard smoking cessation drugs like patches, gum, or varenicline will help you quit, but they are not designed to stop you from gaining weight afterward. Expect modest weight changes, but do not rely on them to maintain your weight.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) significantly reduce major adverse cardiovascular events (MACE-3), cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or heart failure, SGLT2 inhibitors are a first-line treatment option that protects your heart and reduces hospitalization risk, regardless of your blood sugar levels. Consult your doctor about these specific medications.

Bariatric surgery significantly reduces the incidence of mortality and cardiovascular diseases compared to best non-surgical care in patients with obesity.

Bariatric surgery offers a dramatic reduction in mortality and cardiovascular disease risk compared to non-surgical weight loss methods. For patients with obesity, surgery is the most effective intervention for long-term survival and cardiovascular health.

Cardiovascular-Kidney-Metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and high adverse outcome rates.

If you have high blood pressure, diabetes, or kidney issues, recognize that these conditions are linked and worsen each other. Managing one without addressing the others is less effective. Seek integrated care that looks at your heart, kidneys, and metabolic health together to prevent serious complications like heart failure or kidney failure.

Dysfunctional adipose tissue, particularly visceral fat, drives CKM syndrome by secreting proinflammatory and prooxidative products that damage arterial, cardiac, and kidney tissues, leading to insulin resistance and systemic inflammation.

Excess visceral fat is not just stored energy; it actively releases harmful substances that damage your heart, kidneys, and blood vessels. Managing your weight, specifically reducing visceral fat, is a key medical strategy to reduce inflammation and protect your organs.

Chronic Kidney Disease (CKD) significantly amplifies cardiovascular risk, with albuminuria and low GFR being strong predictors of major atherosclerotic and heart failure events, often making CVD the leading cause of death in CKD patients.

If you have kidney disease, your risk of heart problems is significantly higher. Regular monitoring of your heart health, along with managing blood pressure and blood sugar, is essential to prevent heart failure and heart attacks.

Leptin regulates glucose homeostasis through direct actions on POMC neurons, but does not regulate food intake or energy balance through direct actions on these same neurons.

Understanding that leptin's effect on blood sugar is distinct from its effect on hunger helps explain why leptin therapy fails for weight loss in most obese individuals (who are leptin resistant) but might still have metabolic benefits. It shifts focus from 'blocking hunger' to 'metabolic flexibility' and non-POMC pathways.

Obesity can result from an intrinsic metabolic disorder that shifts fuel partitioning toward storage and sequestration in adipose tissue, causing 'internal starvation' and compensatory hyperphagia, independent of excessive energy intake.

This paper argues that for some individuals, obesity is driven by a biological defect in how the body handles fuel (partitioning), not just by eating too much. This biological defect traps energy in fat cells, causing the body to feel starved and triggering hunger. While this explains specific pathological cases in animal models, it suggests that for some humans, treating obesity requires addressing these underlying metabolic shifts rather than just focusing on calorie restriction.

Resting energy expenditure (REE) is primarily determined by the mass and specific metabolic rates of organs and tissues, with fat-free mass (FFM) explaining the majority of variance in REE.

Your resting metabolic rate is largely dictated by your body composition, specifically your fat-free mass (muscle, organs, bone). Maintaining muscle mass is key to preserving metabolic rate.

Acute postexercise elevations in systemic anabolic hormones (testosterone, growth hormone, IGF-1) are neither necessary nor sufficient to stimulate muscle protein synthesis or drive resistance exercise training-induced hypertrophy.

Stop worrying about the exact time of day you train or trying to manipulate your hormones for better gains. Whether you train in the morning or evening, or whether your hormones fluctuate during your menstrual cycle, does not significantly change your ability to build muscle. Focus on consistent, progressive resistance training rather than trying to 'optimize' your hormonal environment.

Obesity is a biologic disorder caused by alterations in CNS pathways controlling energy balance, not a lifestyle failure remediable by willpower alone.

Stop blaming yourself for your weight. Your body is fighting you due to biological mechanisms, not just willpower. Seek medical treatment for obesity just as you would for high blood pressure.

GLP-1 therapy is associated with significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) which are dose-dependent and can lead to discontinuation, although most side effects decrease with continued use.

You will likely experience some gastrointestinal side effects like nausea, diarrhea, or constipation, especially when you start the medication or increase the dose. These symptoms often improve over time. Talk to your doctor about managing these side effects through diet and slow dose titration.

Obesity is fundamentally driven by a disruption in energy balance, mediated by central nervous system resistance to leptin and insulin, and dysregulation of the reward system.

Obesity involves biological resistance to satiety signals (leptin/insulin) and reward dysregulation, meaning willpower alone is often insufficient. Medical interventions that bypass or enhance these signals are often necessary.

Obesity is not caused by a lack of willpower but is the result of complex interactions between individual biological factors and environmental determinants, requiring multifactorial prevention and treatment strategies.

Stop blaming yourself for your weight. Obesity is a complex disease influenced by biology and your environment, not just willpower. Effective management requires addressing both individual health behaviors and the broader environment, such as access to healthy food and safe spaces for activity.

Environmental-level factors, such as the food environment and socioeconomic status, interact with individual-level biological factors to drive obesity, and interventions focusing solely on the individual are suboptimal.

To manage weight effectively, you need to address both your personal habits and your environment. This might mean seeking out healthier food options, advocating for policy changes, and understanding how your biology interacts with your surroundings.

Obesity is a chronic, progressive, relapsing, and treatable multi-factorial neurobehavioral disease, not just a lifestyle choice.

Understand that obesity is a disease with biological drivers, not just a failure of will. This reduces self-blame and opens the door to effective medical and lifestyle interventions.

SGLT2 inhibitors provide consistent cardiovascular benefits (reduced mortality and morbidity) across all BMI classes in heart failure, with no mediating effect of obesity on their efficacy.

If you have heart failure, SGLT2 inhibitors (like Dapagliflozin or Empagliflozin) are a standard, highly effective treatment that works regardless of your weight. They reduce the risk of hospitalization and death. Discuss starting these with your doctor if you are not already on them.

Obesity is fundamentally a chronic metabolic disease characterized by disturbances in energy homeostasis and excessive fat accumulation, driven by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.

Understand that obesity is a complex chronic disease, not a moral failing. Effective management requires addressing biological, genetic, and environmental factors, often necessitating medical interventions alongside lifestyle changes.

Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.

Genetics play a significant role in obesity risk. If you have a family history of obesity, you may have a higher predisposition. However, this does not mean weight management is impossible; tailored medical and lifestyle strategies can be highly effective.

BMI is an insufficient diagnostic tool for obesity because it fails to differentiate between fat mass and lean body mass, leading to misclassification.

Do not rely solely on BMI to determine your health status. It fails to distinguish between muscle and fat. Ask your doctor for more precise assessments like waist circumference or body composition analysis to get a true picture of your metabolic risk.

Higher genetically predicted lifelong BMI causally increases all-cause mortality, with the effect substantially mediated through diabetes.

In this population, higher lifelong BMI significantly increases the risk of premature death, largely by increasing the risk of diabetes. Managing weight and blood sugar are critical for longevity.